132 related articles for article (PubMed ID: 31525573)
1. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
Moreira FL; Marques MP; Duarte G; Lanchote VL
J Pharm Biomed Anal; 2020 Jan; 177():112838. PubMed ID: 31525573
[TBL] [Abstract][Full Text] [Related]
2. Total, Unbound, Renal, and Hepatic Clearances of Raltegravir and the Formation and Elimination Clearances of Raltegravir Glucuronide in Pregnant Women.
Moreira FL; Paz TA; Melli PPDS; Thomaz ML; Marques MP; Rocha A; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Sep; 63(9):1053-1060. PubMed ID: 37260039
[TBL] [Abstract][Full Text] [Related]
3. Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.
Belkhir L; Seguin-Devaux C; Elens L; Pauly C; Gengler N; Schneider S; Ruelle J; Haufroid V; Vandercam B
Sci Rep; 2018 May; 8(1):7359. PubMed ID: 29743555
[TBL] [Abstract][Full Text] [Related]
4. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients.
Yagura H; Watanabe D; Ashida M; Kushida H; Hirota K; Ikuma M; Ogawa Y; Yajima K; Kasai D; Nishida Y; Uehira T; Yoshino M; Shirasaka T
J Infect Chemother; 2015 Oct; 21(10):713-7. PubMed ID: 26233886
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Parsons TL; Marzinke MA
J Pharm Biomed Anal; 2016 Nov; 131():333-344. PubMed ID: 27632783
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke DF; Acosta EP; Cababasay M; Wang J; Chain A; Teppler H; Popson S; Graham B; Smith B; Hazra R; Calabrese K; Bryson Y; Spector SA; Lommerse J; Mirochnick M;
J Acquir Immune Defic Syndr; 2020 May; 84(1):70-77. PubMed ID: 31913995
[TBL] [Abstract][Full Text] [Related]
8. Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma.
Schauer AP; Sykes C; Cottrell ML; Imaz A; Podzamczer D; Kashuba AD
J Pharm Biomed Anal; 2022 Oct; 220():115010. PubMed ID: 36030752
[TBL] [Abstract][Full Text] [Related]
9. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.
Zheng Y; Aboura R; Boujaafar S; Lui G; Hirt D; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Gana I
J Pharm Biomed Anal; 2020 Apr; 182():113119. PubMed ID: 32004775
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.
Cattaneo D; Baldelli S; Cerea M; Landonio S; Meraviglia P; Simioni E; Cozzi V; Fucile S; Gazzaniga A; Clementi E; Galli M; Rizzardini G; Gervasoni C
Antimicrob Agents Chemother; 2012 Dec; 56(12):6132-6. PubMed ID: 22964253
[TBL] [Abstract][Full Text] [Related]
11. A validated method for simultaneous quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients.
Ludna Duarte M; Mikaelle Brandão Silva A; Wellithom Viturino da Silva J; Pereira Santana D; Victor de Castro W; Cláudio Arraes de Alencar L; César Galindo Bedor D; Bastos Leal L
Clin Biochem; 2024 May; 127-128():110765. PubMed ID: 38649089
[TBL] [Abstract][Full Text] [Related]
12. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
[TBL] [Abstract][Full Text] [Related]
13. Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.
Veselinovic M; Yang KH; Sykes C; Remling-Mulder L; Kashuba AD; Akkina R
Virology; 2016 Feb; 489():173-8. PubMed ID: 26771889
[TBL] [Abstract][Full Text] [Related]
14. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
Joseph D; Rose P; Strelkowa N; Schultz A; Garcia J; Elgadi M; Huang F
J Clin Pharmacol; 2015 Apr; 55(4):384-91. PubMed ID: 25352040
[TBL] [Abstract][Full Text] [Related]
15. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
16. Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry.
Yamada E; Takagi R; Sudo K; Kato S
J Pharm Biomed Anal; 2015 Oct; 114():390-7. PubMed ID: 26112927
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
18. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
Maliakkal A; Walmsley S; Tseng A
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.
Wang LZ; Lee LS; Thuya WL; Soon GH; Kong LR; Nye PL; Lee EJ; Flexner C; Goh BC
J Mass Spectrom; 2011 Feb; 46(2):202-8. PubMed ID: 21259392
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.
Zheng Y; Hirt D; Delmas S; Lui G; Benaboud S; Lechedanec J; Tréluyer JM; Chenevier-Gobeaux C; Arezes E; Gelley A; Amri I; Urien S; Bouazza N; Foissac F; Warszawski J; Ghosn J
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32661003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
